Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

Classificação em ações #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Preço da ação
$6.89
Valor de mercado
$43.94B
Variação (1 dia)
-2.91%
Variação (1 ano)
-24.78%
País
CN
Negociar Jiangsu Hengrui Medicine Co., Ltd. (600276)

Categoria

Healthcare
Rácio P/S de Jiangsu Hengrui Medicine Co., Ltd. (600276)
Rácio P/S em October 2026 TTM: 9.37
De acordo com os relatórios financeiros mais recentes e o preço das ações da Jiangsu Hengrui Medicine Co., Ltd., o rácio P/S atual (TTM) é 9.37. No final de 2024, o rácio P/S era 10.39.
Histórico do rácio P/S da Jiangsu Hengrui Medicine Co., Ltd. de 2001 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
2026 (TTM) 9.37 -23.96%
2025 12.32 18.54%
2024 10.39 -17.13%
2023 12.54 8.76%
2022 11.53 -7.68%
2021 12.49 -41.32%
2020 21.29 28.72%
2019 16.54 47.69%
2018 11.20 -3.36%
2017 11.59 44.55%
2016 8.02 -6.62%
2015 8.58 63.97%
2014 5.24 -9.71%
2013 5.80 21.57%
2012 4.77 -5.76%
2011 5.06 -38.70%
2010 8.26 10.18%
2009 7.49 29.72%
2008 5.78 -34.42%
2007 8.81 78.87%
2006 4.92 420.22%
2005 0.95 14.31%
2004 0.83 -8.27%
2003 0.90 -28.02%
2002 1.25 -16.11%
2001 1.50 0.00%
Rácio P/S de empresas semelhantes ou concorrentes